Source-grounded facts extracted from ZIMMER BIOMET HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ZIMMER BIOMET HOLDINGS, INC. reported first quarter ended March 31, 2023 results: revenue $1.831 billion, net income $232.5 million, EPS $1.11.
“The Company reported first quarter net sales of $1.831 billion, an increase of 10.1% over the prior year period, and an increase of 13.2% on a constant currency 1 basis. Net earnings for the first quarter were $232.5 million, or $396.8 million on an adjusted 1 basis. Diluted earnings per share were $1.11 for the first quarter, and adjusted 1 diluted earnings per share were $1.89.”
Earnings Releases
ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter and year ended December 31, 2022.
“On February 3, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and year ended December 31, 2022.”
Governance Changes
ZIMMER BIOMET HOLDINGS, INC.: Amended and restated the bylaws to implement procedural mechanisms related to stockholder nominations of directors under Rule 14a-19, including certification requirements, nullification of nominations for non-compliance, reservation of white proxy cards, and other technical changes (effective 2022-12-14).
“On December 14, 2022, the Board of Directors of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet” or the “Company”) amended and restated the Company’s Restated Bylaws (as so amended and restated, the “Bylaws”), primarily to implement certain procedural mechanisms related to stockholder nominations of directors under Rule 14a-19 (“Rule 14a-19”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These amendments took immediate effect.”
Earnings Releases
ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter ended September 30, 2022.
“On November 2, 2022, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2022.”
Derek Davis changed role as Vice President, Finance Integration at ZIMMER BIOMET HOLDINGS, INC..
“Derek Davis, who served as the Company’s Interim Controller and Chief Accounting Officer and had assumed the responsibilities of the Company’s principal accounting officer during the search process that led to Mr. Stellato’s hiring, will continue in his role as the Company’s Vice President, Finance Integration.”
Paul Stellato was appointed as Vice President, Controller and Chief Accounting Officer at ZIMMER BIOMET HOLDINGS, INC..
“Paul Stellato has been appointed Vice President, Controller and Chief Accounting Officer of the Company.”
Derek Davis was appointed as Interim Controller and Chief Accounting Officer at ZIMMER BIOMET HOLDINGS, INC..
“the Company has determined that Derek Davis, the Company’s Vice President, Finance Integration, will serve as the Interim Controller and Chief Accounting Officer, and principal accounting officer, of the Company, effective upon Ms. Nichol’s departure on November 26, 2021.”
Carrie Nichol departed as Vice President, Controller and Chief Accounting Officer at ZIMMER BIOMET HOLDINGS, INC..
“On October 29, 2021, Zimmer Biomet Holdings, Inc. (the “Company”) announced that Carrie Nichol, the Vice President, Controller and Chief Accounting Officer, and the principal accounting officer, of the Company, will be departing from the Company effective November 26, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.